In vitro and in vivo evaluation of novel ligands for radioimmunotherapy

Nuclear Medicine and Biology

Volumn 33, Issue 4, 2006, Pages 459-467

  Chong, Hyun Soon ^a,b   Milenic, Diane E ^a   Garmestani, Kayhan ^a   Brady, Erik D ^a   Arora, Hans ^a   Pfiester, Candice ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Illinois Institute of Technology   (United States)

Author keywords

Biodistribution; Chelates radiolabeled with 177Lu, 90Y, 212Pb, and 213Bi; PIP DTPA; Radioimmunotherapy; Serum stability

Indexed keywords

2,6 BIS[N,N BIS(CARBOXYMETHYL)AMNIOMETHYL] 1 PIPERIDINEACETIC ACID; 6,9,15 TRIS CARBOSYMETHYL 3,6,9,15 TETRAAZABICYCLO[9.3.1]PENTADEC 3 YL] ACETID ACID; [2 (4,7 BIS CARBOXYMETHYL [1,4,7]TRIAZACYCLONONAN 1 YL ETHYL] 2 CARBONYLMETHYL AMINO] TETRAACETIC ACID; [{4 CARBOXYMETHYL 7 [2 (CARBOXYMETHYLAMINO) ETHYL] PERHYDRO 1,4,7 TRIAZONIN 1 YL} ACETIC ACID; BISMUTH 213; CHELATING AGENT; LEAD 212; LUTETIUM 177; UNCLASSIFIED DRUG; YTTRIUM 90; {2,7 BIS [(BIS CARBOXYMETHYL AMINO) METHYL] AZEPAN 1 YL} ACETIC ACID;

ARTICLE; CHEMICAL STRUCTURE; CONJUGATION; FEMUR; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LIVER; MOUSE; NONHUMAN; PLASMA CLEARANCE; RADIOACTIVITY; RADIOIMMUNOTHERAPY;

ACETIC ACIDS; ANIMALS; AZEPINES; BICYCLO COMPOUNDS, HETEROCYCLIC; CHELATING AGENTS; DRUG DESIGN; FEMALE; GLYCINE; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; PIPERIDINES; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33646762819     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.03.004     Document Type: Article

References (33)

1. Knox S.J., and Meredith R.F. Clinical radioimmunotherapy. Semin Radiat Oncol 10 (2000) 73-93
2. Schubiger P.A., Alberto R., and Smith A. Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug Chem 7 (1996) 165-179
3. Srivastava S.C. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother Radiopharm 11 (1996) 43-50
4. Juweid M., Neumann R.D., and Paik C.H. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 52 (1992) 5144-5153
5. Jurcic J.G., McDevitt M.R., Sgouros G., Ballangrud A.M., Finn R.D., Ma D., et al. Phase 1 trial of targeted alpha particle therapy for myeloid leukemia with 213-Bi-HuM195(anti-CD33). Proc Am Soc Clin Oncol 18 (1999) 7-12
6. 213Bi-alpha radioimmunotherapy for multiple myeloma. Clin Cancer Res 5 10 Suppl (1999) 3165s-3170s
7. 213Bi, and their decay chain related radionuclides for therapeutic applications. Chem Rev 101 (2001) 2019-2036
8. Moi M.K., Meares C.F., and DeNardo S.J. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N′ ′,N′′′-tetraacetic acid and study of its yttrium(III) complex. J Am Chem Soc 110 (1988) 6266-6267
9. Kumar K., Magerstadt M., and Gansow O.A. Lead(II) and Bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and tteta. J Chem Soc Chem Commun (1989) 145-146
10. Ruegg C.L., Anderson-Berg W.T., Brechbiel M.W., Mirzadeh S., Gansow O.A., and Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 50 (1990) 4221-4226
11. Kumar K., Chang C.A., and Tweedle M.F. Equilibrium and kinetic studies of lanthanide complexes of macrocyclic polyamino carboxylates. Inorg Chem 32 (1993) 587-593
12. Kodama M., Koike T., Mahatma A.B., and Kimura E. Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaazacyclopentadecane-N,N′,N′′,N′ ′′,N′′′′-pentaacetic acid and 1,4,7,10,13,16-hexaazacyclcootadecane-N,N′,N′′,N′ ′′,N′′′′-hexaacetic acid. Inorg Chem 30 (1991) 1270-1273
13. Harrison A., Walker C.A., Parker D., Jankowski K.J., and Cox J.P. The in vivo release of 90-Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med Biol 18 (1991) 469-476
14. 212Bi for a-particle mediated radioimmunotherapy. J Chem Soc Chem Commun (1991) 1169-1170
15. 90Y radioimmunotherapy. Bioconjug Chem (1991) 187-194
16. 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int J Radiat Oncol Biol Phys 34 (1996) 609-616
17. McMurry T.J., Pippin C.G., Wu C., Deal K.A., Brechbiel M.W., Mirzadeh S., et al. Physical parameters and biological stability of yttrium (III) diethylenetriaminepentaacetic acid derivative conjugates. J Med Chem 41 (1998) 3546-3549
18. Camera L., Kinuya S., Garmestani K., Wu C., Brechbiel M.W., Pai L.H., et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 35 (1994) 882-889
19. Knox S.J., Goris M.L., Trisler K., Negrin R., Davis T., Liles T.-M., et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2 (1996) 457-470
20. Scott M.E., Schlom J., Siler K., Milenic D.E., Eggensperger D., Colcher D., et al. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer 73 3 Suppl (1994) 993-998
21. Chappell L.L., Ma D., Milenic D.E., Gramestani K., Venditto V., Beitzel M.P., et al. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′ ′-tetraacetic acid for radiolabeling proteins. Nucl Med Biol 30 (2003) 581-595
22. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1 (1995) 1447-1454
23. 177Lμ-CC49: a phase I/II study. Gynecol Oncol 65 (1997) 94-101
24. Chong H.S., Garmestani K., Ma D., Milenic D.E., Overstreet T., and Brechbiel M.W. Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics. J Med Chem 45 (2002) 3458-3464
25. 111In labeled Herceptin. Nucl Med Biol 29 (2002) 599-606
26. Garmestani K., Yao Z., Zhang M., Wong K., Park C.W., Pastan I., et al. Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. Nucl Med Biol 28 (2001) 409-418
27. Chappell L.L., Dadachova E., Milenic D.E., Garmestani K., Wu C., and Brechbiel M.W. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203-Pb and 212-Pb. Nucl Med Biol 27 (2000) 93-100
28. Chong H.S., Garmestani K., Bryant L.H., and Brechbiel M.W. Synthesis of DTPA analogues derived from piperidine and azepane: potential contrast enhancement agents for magnetic resonance imaging (MRI). J Org Chem 66 (2001) 7745-7750
29. McMurry T.J., Brechbiel M.W., Kumar K., and Gansow O.A. Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjugate Chem 3 (1992) 108-117
30. Chong H.S., Garmestani K., Bryant L.H., Milenic D.E., Overstreet T., Birch N., et al. Synthesis and evaluation of novel macrocyclic and acyclic Ligands as contrast enhancement agents for Magnetic Resonance Imaging (MRI). J Med Chem (2006) [in Press]
31. Woods M., Kovacs Z., Kiraly R., Brucher E., Zhang S., and Sherry A.D. Solution dynamics and stability of lanthanide (III) (S)-2-(p-nitrobenzyl)DOTA complexes. Inorg Chem 43 (2004) 2845-2851
32. Yoo J., Reichert D.E., and Welch M.J. Comparative in vivo behavior studies of cyclen-based copper-64 complexes: regioselective synthesis, x-ray structure, radiochemistry, log P, and biodistribution. J Med Chem 47 (2004) 6625-6637
33. Li W.P., Ma D.S., Higginbotham C., Hoffman T., Ketring A.R., Cutler C.S., et al. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol 28 (2001) 145-154